Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Omic Insights on Unfolding Saga of COVID-19.
Kaur A, Chopra M, Bhushan M, Gupta S, Kumari P H, Sivagurunathan N, Shukla N, Rajagopal S, Bhalothia P, Sharma P, Naravula J, Suravajhala R, Gupta A, Abbasi BA, Goswami P, Singh H, Narang R, Polavarapu R, Medicherla KM, Valadi J, Kumar S A, Chaubey G, Singh KK, Bandapalli OR, Kavi Kishor PB, Suravajhala P. Kaur A, et al. Among authors: singh kk, singh h. Front Immunol. 2021 Oct 20;12:724914. doi: 10.3389/fimmu.2021.724914. eCollection 2021. Front Immunol. 2021. PMID: 34745097 Free PMC article. Review.
Grand challenges in bioinformatics education and training.
Işık EB, Brazas MD, Schwartz R, Gaeta B, Palagi PM, van Gelder CWG, Suravajhala P, Singh H, Morgan SL, Zahroh H, Ling M, Satagopam VP, McGrath A, Nakai K, Tan TW, Gao G, Mulder N, Schönbach C, Zheng Y, De Las Rivas J, Khan AM. Işık EB, et al. Among authors: singh h. Nat Biotechnol. 2023 Aug;41(8):1171-1174. doi: 10.1038/s41587-023-01891-9. Nat Biotechnol. 2023. PMID: 37568018 No abstract available.
Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease.
Chopra HK, Khullar D, Nair T, Wander GS, Ponde CK, Ray S, Nanda NC, Kasliwal RR, Rana DS, Kirpalani A, Sawhney J, Chandra P, Mehta Y, Kumar V, Tewari S, Pancholia AK, Kher V, Bansal S, Mittal S, Kerkar P, Sahoo PK, Hotchandani R, Prakash S, Chauhan N, Rastogi V, Jabir A, Shanmugasundaram S, Tiwaskar M, Sinha A, Gupta V, Mishra SS, Routray SN, Omar AK, Swami OC, Jaswal A, Alam S, Passey R, Rajput R, Paul J, Kapoor A, Prabhakar D, Chandra S, Malhotra P, Singh VP, Bansal M, Shah P, Jain S, Bhargava M, Vijayalakshmi IB, Varghaese K, Jain D, Goel A, Gaur N, Tandon R, Moorthy A, George S, Katyal VK, Mantri RR, Mehrotra R, Bhalla D, Mittal V, Rao S, Jagia M, Singh H, Awasthi S, Sattur A, Mishra R, Pandey A, Chawla R, Jaggi S, Sehgal B, Sehgal A, Goel N, Gupta R, Kubba S, Chhabra A, Bagga S, Shastry NR. Chopra HK, et al. Among authors: singh h. J Assoc Physicians India. 2024 May;72(5):77-88. doi: 10.59556/japi.72.0543. J Assoc Physicians India. 2024. PMID: 38881115
FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Fourie Zirkelbach J, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N. Barbato MI, et al. Among authors: singh h. Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949. Online ahead of print. Clin Cancer Res. 2024. PMID: 38875108
7,323 results